Clinical trialNCT06011577TerminatedPhase 3Interventional

Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD

SponsorLevomecor Inc.Enrollment27DepressionMajor Depressive Disorder

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of REL-1017 in patients with major depressive disorder (MDD).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Paul Greene, PhD
Relmada Therapeutics
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

36 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Relmada Site
Dothan, Alabama, United States
Relmada Site
Homewood, Alabama, United States
Relmada Site
Anaheim, California, United States
Relmada Site
Lafayette, California, United States
Relmada Site
Newport Beach, California, United States
Relmada Site
Orange, California, United States
Relmada Site
Redlands, California, United States
Relmada Site
Sherman Oaks, California, United States
Relmada Site
Farmington, Connecticut, United States
Relmada Site
Brandon, Florida, United States
Relmada Site
Hialeah, Florida, United States
Relmada Site
Jacksonville, Florida, United States
Relmada Site
Miami, Florida, United States
Relmada Site
Miami, Florida, United States
Relmada Site
Okeechobee, Florida, United States
Relmada Site
Tampa, Florida, United States
Relmada Site
Springfield, Illinois, United States
Relmada Site
Baltimore, Maryland, United States
Relmada Site
Mankato, Minnesota, United States
Relmada Site
Toms River, New Jersey, United States
Relmada Site
Brooklyn, New York, United States
Relmada Site
Cedarhurst, New York, United States
Relmada Site
New York, New York, United States
Relmada Site
Philadelphia, Pennsylvania, United States
Relmada Site
Franklin, Tennessee, United States
Relmada Site
Memphis, Tennessee, United States
Relmada Site
Austin, Texas, United States
Relmada Site
Bellaire, Texas, United States
Relmada Site
Friendswood, Texas, United States
Relmada Site
Houston, Texas, United States
Relmada Site
Wichita Falls, Texas, United States
Relmada Site
Clinton, Utah, United States
Relmada Site
Draper, Utah, United States
Relmada Site
Rutland, Vermont, United States
Relmada Site
Charlottesville, Virginia, United States
Relmada Site
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PlaceboREL-1017

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 17 Aug 2023
Primary completion: 19 Dec 2024
Completion: 19 Dec 2024
Last update posted: 10 Jul 2026
Registered enrollment: 27
Registry id: NCT06011577

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.